You can write in Portuguese, English, Spanish or French. The search doesn't link to accents or uppercase letters, separates the words (all must appear) and also searches for the equivalent word in other languages: "transplant" finds "transplant" and "trasplante". Searches in the original titles, translated titles into Portuguese, descriptions and abstracts. MielomaAI.
In the last 3 months. From the older news, only the title and link remain in the archive. Those that have about 1 year may no longer be up to date
Looking for words: biespecificos. Saltar para: notícias recentes (19) · My Hematologia (3) · explanations (7) · arquivo (6)
Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific AntibodyNational Institutes of Health (NIH) | (.gov) (EUA) · 23:37 InvestigaçãoEUA
REMS Certification and Team-Wide Training for Bispecific Administration in Multiple MyelomaCancerNetwork (EUA) · 15:05 Acesso e saúde públicaEUARalph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
How Etentamig Stands Out From Other BCMA BispecificsTargeted Onc (EUA) · 22:00 TratamentosEUAPeter Voorhees, MD, explains how etentamig differentiates itself from other BCMA bispecifics for multiple myeloma through a strategic engineering choice: a low-affinity CD3 binding domain. By intentionally reducing this affinity, the design aims to mitigate severe cytokine release syndrome. It can also be given on an…
CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple MyelomaCancerNetwork (EUA) · 13:13 TratamentosEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss the potential role of cereblon E3 ligase modulators (CELMoDs) following chimeric antigen receptor (CAR) T-cell therapy and in combination with bispecific antibodies for multiple myeloma.
BCMA-Directed Bispecifics and ADCs Broaden Treatment Sequencing Options in R/R MyelomaOncLive (EUA) · 14:06 TratamentosEUADuring a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.
Early Relapsed Myeloma: No Efficacy Hierarchy Established Between CAR T Cells and Bispecific AntibodiesOncodaily (Reino Unido) · 08:00 TratamentosReino UnidoEarly Relapsed Myeloma: No Efficacy Hierarchy Established Between CAR T Cells and Bispecific Antibodies / Bispecific antibodies, cancer, CAR-T, Headlines,
Chongqing drugmaker launches China's first domestically developed BCMA/CD3 bispecific antibodyChina Daily (China) · 08:00 TratamentosChina
Outpatient Models and Prophylactic Measures Help Bring Bispecifics Into Community Practice for R/R MyelomaOncLive (EUA) · 08:00 Doentes e associaçõesEUAFaculty at an OncLive Scientific Interchange and Workshop discussed operationalizing outpatient bispecific antibody therapy for relapsed/refractory multiple myeloma.
Tocilizumab Prophylaxis, Caregiver Readiness, and Chair Time Shape Community Bispecific Programs in R/R MyelomaOncLive (EUA) · 08:00 Doentes e associaçõesEUACommunity hematologists/oncologists discussed bispecific antibody integration in community practice for relapsed/refractory multiple myeloma.
Bispecific antibodies increase the risk of infections and require new prevention strategies.My Hematologia — pesquisa "mieloma" (página 2) (Portugal) · 14:25 TreatmentsPortugalPTSpecific antibodies that recruit T cells are transforming the treatment of various hematological diseases, such as non-Hodgkin lymphoma and multiple myeloma, but repeated use is associated with a significant risk of infection. An article published in Blood proposes a practical approach to prevent…
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trialFierce Biotech (EUA) · 07:00 InvestigaçãoEUA
Teclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System AnalysisOncodaily · 11:23 TratamentosTeclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System Analysis / BCMA, BCMA × CD3 bispecific antibody, Daratumumab, FDA
T-Cell Fitness and Treatment Sequencing in Multiple MyelomaCancerNetwork (EUA) · 08:00 TratamentosEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss how T-cell fitness may influence treatment sequencing in multiple myeloma, particularly as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies become increasingly important treatment options.
Dr. Rahul Banerjee on the future of myeloma careFred Hutchinson Cancer Center (Reino Unido) · 07:00 TratamentosReino UnidoRahul Banerjee, MD, FACP joins Petros Grivas, MD, PhD to discuss how CAR T cell-therapy and bispecific antibodies are changing myeloma care, ongoing Fred Hutch trials, working with community oncologists, and the team approach behind it all.
AbbVie (ABBV) Seeks FDA Approval For Etentamig In Multiple MyelomaYahoo Finance (EUA) · 07:00 Acesso e saúde públicaEUAAbbVie (NYSE: ABBV) has submitted a Biologics License Application to the FDA for its multiple myeloma candidate etentamig. The filing is backed by a pivotal Phase 3 trial in relapsed or refractory multiple myeloma that met its primary endpoint. Etentamig is a second generation BCMA x CD3 bispecific antibody that is ad…
AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple MyelomaPR Newswire (Internacional) · 07:00 Acesso e saúde públicaInternacional– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support...
BLA Submitted for Etentamig in Relapsed/Refractory MyelomaTargeted Onc (EUA) · 07:00 Acesso e saúde públicaEUAEtentamig, a BCMAxCD3 bispecific antibody, was submitted for potential FDA approval based on the phase 3 CERVINO trial in relapsed/refractory multiple myeloma.
CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myelomaGlobeNewswire (Internacional) · 07:00 Acesso e saúde públicaInternacionalIf approved, TALVEY® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple...
Zenbexus PFS Data Suggest Utility In Community Treatment Of Multiple MyelomaScrip (China) · 07:00 TratamentosChinaFollowing approval in August, Bristol Myers Squibb reports Phase III PFS data that may make the oral CELMoD an ideal option for community care centers less suited to administering CAR-T and bispecific antibodies.
Click on an article to open it on the side with the summary. MielomaAI And the link to the source.
New treatment options allow for control of the patient with multiple myeloma.InterviewsMy Hematologia · 5 Sep 2025The article reports a discussion about the treatment of multiple myeloma (MM) led by hematologist Catarina Geraldes from the Coimbra ULSS at a hematology event. Read more →
Multiple myeloma: a combination strategy of multiple mechanisms of action allows for sustained disease control.InterviewsMy Hematologia · November 8, 2024This article reports on a presentation about the use of bispecific anti-BCMA drugs in the treatment of multiple myeloma, particularly in patients who have already received other treatments such as proteasome inhibitors or anti-CD38 antibodies. Read more →
Treatment of multiple myeloma: The European Union grants conditional market authorization for teclistamab.NewsMy Hematologia · September 9, 2022Teclistamab is a new drug approved by the European Union to treat multiple myeloma in advanced stages when other treatments have not worked. It is an antibody that acts on two parts of the myeloma cells, helping to destroy the cancerous cells. Read more →
- Bispecifics
- Antibodies with two “arms”: one grabs the T lymphocyte and the other the myeloma cell, joining them so that the lymphocyte destroys. Examples: teclistamab, elranatamab, talquetamab.
- BCMA
- The protein found on the surface of myeloma cells (B cell maturation antigen). It is the target of CAR-T Carvykti and the bispecific teclistamab and elranatamab.
- This is a gene associated with multiple myeloma.
- Another protein on myeloma cells, different from BCMA. It is the target of the bispecific talquetamab (Talvey).
- T lymphocytes
- White blood cells that attack cancerous cells. These are the ones that myeloma patients and specialists put to work attacking the myeloma, and these are used to manufacture CAR-T.
- Cytokine release syndrome
- Immune system reaction that can occur with CAR-T and bispecifics: fever, chills, low blood pressure. Almost always mild and treatable; therefore, initial doses are monitored.
- ICANS
- Effect on the brain of CAR-T and bispecifics: confusion, difficulty speaking or writing, drowsiness. Generally resolves, but must be reported promptly.
- Extramedullary Disease
- Multiple myeloma with tumors in organs or soft tissues (skin, liver, lymph nodes, nervous system), in diagnosis or, more frequently, in relapses. How it is managed or treated: Intensive treatment; CAR-T and bispecifics are options in relapse; clinical trials. Risk: High risk. See the film "Types of myeloma" →
Access and public health
- The FDA approves TECVAYLI™ (teclistamab), the first bispecific antibody that links T cells, for patients with multiple myeloma in relapse or refractory status. 4 years ago · Johnson & Johnson · 25/10/2022
Research
- The specific combination of J&J reduces the risk of myeloma progression by 89% in a Phase 3 study. ↗ · Fierce Pharma · 23/07/2026
- Bispecific Antibody FcRH5xCD3 cevostamab in recurrent or refractory multiple myeloma: a Phase 1 trial ↗ · Nature · 22/07/2026
Treatments
- The new TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hialuronidase-fihj) demonstrate the power of a bispecific combination in relapsed or refractory multiple myeloma at the start of treatment. ↗ · PR Newswire · 06/13/2026
- Early use of bispecific antibodies in multiple myeloma: current data and open questions · ASCO Daily News · January 29, 2026
- Janssen celebrates the first global approval of TECVAYLI® (teclistamab) with European authorization as the first biespecific antibody of its class for multiple myeloma. 4 years ago · Johnson & Johnson · 24/08/2022
